As the U.S. economy continues to stabilize in the wake of the COVID-19 pandemic, prescription volumes continue to rebound as well. The overall market growth for prescription drugs from May 21–28 hit 21% year over year, according to IQVIA data. The growth rate in the prior two weeks was 13%. New prescription growth from May…
U.S. pharma industry sees prescription sales dip again
The U.S. pharmaceutical market dipped 4.1% year-over-year in the most recent quarter-to-date figures, according to recent IQVIA research. New prescription sales fell 4.4%. Brand-name drug sales, however, saw a modest growth rate of 1.8% while generic drug sales, which made up 80% of all sales, fell 4.5% in the quarter. One bright spot in the…